[{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Hong Kong Winhealth Pharma Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Diacerein","moa":"CASP1\/IL-1-beta","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"TWi Biotechnology \/ Hong Kong Winhealth Pharma Group","highestDevelopmentStatusID":"8","companyTruncated":"TWi Biotechnology \/ Hong Kong Winhealth Pharma Group"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Diacerein","moa":"TYK2\/JAK1","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Accro Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accro Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Accro Bioscience \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Diacerein

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have shown that AC-201 effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1.

                          Product Name : AC-201

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          May 24, 2023

                          Lead Product(s) : Diacerein

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Strategic partnership grants Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin...

                          Product Name : AC-203

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 01, 2021

                          Lead Product(s) : Diacerein

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase II

                          Sponsor : Hong Kong Winhealth Pharma Group

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank